TY - BOOK ID - 133803680 TI - Tuberculosis Drug Discovery and Development 2019 AU - Riccardi, Giovanna AU - Sala, Claudia PY - 2020 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Research & information: general KW - Biology, life sciences KW - mycobacteria KW - tuberculosis KW - multi-drug resistance KW - drug discovery KW - promiscuous targets KW - Mycobacterium tuberculosis KW - rifampin KW - isoniazid KW - mechanisms of resistance KW - mutations KW - granulomas KW - caseum KW - cell envelope KW - dormancy KW - delpazolid KW - macozinone KW - DprE1 inhibitor KW - clinical studies KW - discovery KW - mode of action KW - drug resistance KW - toxicity KW - target KW - energy metabolism KW - electron transport chain KW - oxidative phosphorylation KW - bedaquiline KW - Q203 KW - MID3 KW - pharmacokinetics KW - pharmacodynamics KW - drug-drug interactions KW - in vitro KW - in vivo KW - drug development KW - tuberculosis treatment KW - biomarkers KW - drug combination KW - clinical trial KW - BCG KW - tuberculosis vaccines KW - TBVI KW - EDCTP KW - IAVI KW - CTVD KW - host-directed therapy KW - anti-virulence compounds KW - TB KW - post-treatment sequelae KW - surgery KW - pulmonary rehabilitation KW - Carlo Forlanini KW - artificial pneumothorax KW - n/a KW - structure-based drug design KW - target-based drug design KW - PknB KW - PknG KW - DNA gyrase KW - antibiotic KW - mycobacterium KW - genomics KW - transcriptomics KW - proteomics KW - metabolomics KW - lipidomics KW - target identification KW - mechanism of action KW - antimicrobial drug resistance (AMR) KW - target-based screening KW - phenotypic screening KW - antituberculosis agents KW - antimycobacterial KW - anti-TB drug pipeline KW - privileged targets KW - lead generation UR - https://www.unicat.be/uniCat?func=search&query=sysid:133803680 AB - Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue. ER -